<DOC>
	<DOCNO>NCT00003401</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase II trial study effectiveness peripheral stem cell transplantation plus combination chemotherapy treat patient multiple myeloma treat long 12 month .</brief_summary>
	<brief_title>Peripheral Stem Cell Transplantation Plus Combination Chemotherapy Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate complete partial response multiple myeloma patient receive peripheral blood stem cell support gemcitabine high dose carmustine melphalan follow consolidation therapy gemcitabine plus cyclophosphamide/dexamethasone/etoposide/cisplatin ( DCEP ) dexamethasone/paclitaxel/cisplatin . II . Evaluate incidence early death comparison historical data patient population . III . Evaluate feasibility chemotherapy gemcitabine plus DCEP dexamethasone/paclitaxel/cisplatin follow autotransplantation patient . OUTLINE : Patients receive gemcitabine IV 100 minute day -5 6 hour administration carmustine IV 2 hour day -2 , follow melphalan IV 20 minute day -1 . Patients receive intravenous CD34 peripheral blood stem cell day 0 . At 3 month 9 month , patient adequate hematologic count receive cyclophosphamide IV , oral dexamethasone , etoposide IV , cisplatin IV 4 day . On day 3 continuous infusion , gemcitabine give 100 minute . At 6 12 month autotransplant , patient receive oral dexamethasone day 1-4 , paclitaxel IV 6 hour day 2 , cisplatin IV 24 hour day 3 . Patients follow every 6 week 3 month death . PROJECTED ACCRUAL : Approximately 24-63 patient accrue within 2.5 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven multiple myeloma great 12 month prior therapy Bone marrow plasmacytosis least 30 % protein criterion present No obvious myelodysplastic change bone marrow No CNS disease PATIENT CHARACTERISTICS : Age : 18 70 Performance status : SWOG 02 ( 34 acceptable base solely bone pain ) Life expectancy : Not specify Hematopoietic : CD34+ least 4,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL SGOT SGPT great 4 time upper limit normal No active chronic hepatitis liver cirrhosis Renal : Creatinine great 3.0 mg/dL Cardiovascular : LVEF great 50 % Pulmonary : FEV1 FVC least 50 % predict DLCO least 50 % predict Patients unable complete pulmonary function test must CT scan chest acceptable arterial blood gas PO2 great 70 Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No active infection require IV antibiotic PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior chemotherapy Endocrine therapy : Prior steroid therapy allow Radiotherapy : At least 4 week since prior radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>